两性霉素B联合用药的研究进展

两性霉素B （amphotericin B,AmB）属于多烯类抗真菌药物,因其耐药率低、抗菌谱广,被称为治疗深部真菌感染的“金标准”,但是严重的毒副作用（尤其是肾毒性）大大限制了AmB在临床上的应用.在目前高效、低毒的抗真菌药物较少的情况下,联合使用不同作用机制的抗真菌药物,使其发挥协同作用,缩短疗程、减少药物毒副作用、扩大药物抗菌谱、避免耐药性的出现,是当前深部真菌感染治疗研究领域的一个重要研究方向.本文对AmB与不同种类抗真菌药物联合使用的研究进展作一综述.

Research progress in the combined use of amphotericin B

Objective Amphotericin B （AmB） was a polyene antifungal agent. Because of its lowest resistance rate and broad antibiotic spectrum, AmB was considered as a ＂gold standard＂for the treatment of deep fungal infections. However, the occur- rence of toxicity and serious side effects, especially renal toxicity,greatly limited the application of AmB in clinical antifungal therapy. Due to the lack of antifungal with high efficiency and low toxicity, the combination of antifungal agents with different mechanisms of ac- tion was a promising research direction. The advantage of the combinations was the course of treatment shortened, drug side effects re- duced, the antibacterial spectrum expanded, and drug resistance avoided. The research progress in the combined use of AmB with dif- ferent types of antifungal compounds were introduced in this article.